

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Vincent Medical Holdings Limited**

**永勝醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 1612)

### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that with effect from 1 February 2017:

- (1) Mr. Guo Pengcheng has been appointed as a non-executive Director; and
- (2) Prof. Yung Kai Leung has been appointed as an independent non-executive Director.

The board (the “**Board**”) of directors (the “**Directors**”) of Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that with effect from 1 February 2017, Mr. Guo Pengcheng has been appointed as a non-executive Director and Prof. Yung Kai Leung has been appointed as an independent non-executive Director.

#### **PARTICULARS OF MR. GUO PENGCHENG**

Mr. Guo Pengcheng, aged 55, graduated from the Shanghai University of Technology with a bachelor’s degree in mechanical engineering in 1983.

Mr. Guo has over 30 years of experience in business advisory work and cross-border investments. During the period from 1986 to 2004, Mr. Guo worked in various organizations where he was responsible for inbound and outbound business development and business expansion from the People’s Republic of China. From 2009 to 2015, Mr. Guo was the operating partner of Orchid Asia Private Equity Fund where he was responsible for operational due diligence and post-investment management for listing applicants on The Stock Exchange of Hong Kong Limited.

Since 2015, Mr. Guo has acted as the senior investment consultant of Dong Yin Development (Holdings) Limited, an indirect substantial shareholder interested in 33,000,000 shares of the Company, representing approximately 5.17% of the issued share capital of the Company.

Mr. Guo is responsible for providing strategic guidance to the Group on operational efficiency enhancement.

Mr. Guo has entered into a service agreement with the Company for a term of three years commencing from 1 February 2017 provided that at any time during the term of appointment, either party may terminate the appointment by giving to the other not less than three months' notice in writing. His appointment is subject to retirement by rotation and re-election at an annual general meeting in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Pursuant to Mr. Guo's service agreement, he is entitled to a monthly remuneration of HK\$15,000. The emolument of Mr. Guo was determined with reference to his duties and responsibilities, the Company's performance as well as the remuneration benchmark in the industry and the prevailing market conditions.

#### **PARTICULARS OF PROF. YUNG KAI LEUNG**

Prof. Yung Kai Leung, aged 67, graduated from Brighton University, the United Kingdom with a bachelor's degree in electronic engineering in 1975. He further obtained a master's degree in automatic control systems from Imperial College, the United Kingdom in 1976 and his doctorate in microprocessor applications in process control from the Plymouth University, the United Kingdom in 1985. He is a fellow member of the Hong Kong Institute of Engineers and a fellow of the Hong Kong Academy of Engineering Sciences. In 2015, Prof. Yung was awarded the Bronze Bauhinia Star for his contributions to scientific research.

Since 1986, Prof. Yung held various positions at The Hong Kong Polytechnic University. Prof. Yung has been a professor in the Department of Industrial and Systems Engineering at The Hong Kong Polytechnic University since 2001.

Prof. Yung is responsible for participating in meetings of the Board to bring an independent perspective and judgment on issues of strategy, performance, accountability, resources, key appointments and standards of conduct and transactions which are material to the Group as and when required.

Prof. Yung has entered into a service agreement with the Company for a term of three years commencing from 1 February 2017 provided that at any time during the term of appointment, either party may terminate the appointment by giving to the other not less than three months' notice in writing. His appointment is subject to retirement by rotation and re-election at an annual general meeting in accordance with the articles of association of the Company and the Listing Rules. Pursuant to Prof. Yung's service agreement, he is entitled to a monthly remuneration of HK\$15,000. The emolument of Prof. Yung was determined with reference to his duties and responsibilities, the Company's performance as well as the remuneration benchmark in the industry and the prevailing market conditions.

As at the date of this announcement, Prof. Yung is interested in 100,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO"). Prof. Yung has also confirmed his independence for the purpose of Rule 3.13 of the Listing Rules.

## **CONCLUSION**

As at the date of this announcement and save as disclosed above, none of Mr. Guo and Prof. Yung (i) has any interest in the shares of the Company or its associated corporations which is required to be disclosed under Part XV of the SFO; (ii) has any relationship with other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) has held any directorships in listed public companies in the last three years.

Save as disclosed above, there are no other matters concerning Mr. Guo and Prof. Yung that need to be brought to the attention of the shareholders of the Company, and there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend a warm welcome to Mr. Guo and Prof. Yung on their new appointments.

By order of the Board  
**Vincent Medical Holdings Limited**  
**Choi Man Shing**  
*Chairman and Executive Director*

Hong Kong, 1 February 2017

*As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Ms. Liu Pui Ching, Mr. Amir Gal Or, Mr. Poon Lai Yin Michael (alternate to Mr. Amir Gal Or) and Mr. Guo Pengcheng as non-executive Directors, and Mr. Chan Ling Ming, Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.*